Search Results - hybridoma+%2f+antibody

9 Results

Sort By:

Engineering B cells to obtain CD40 signals from antigen instead of CD40Ligand (CD40L)

Designing universal donor B cells that will respond to antigen independently of T cell boost Methods to link CD40 signaling to antigen binding independently of CD40L binding in order to potentiate B-cell responses. Vaccines increase immunity against infections by stimulating B cells to produce antibodies against the infectious agent. In addition...

Published: 12/6/2023 | Updated: 12/6/2023 | Inventor(s): Justin Taylor, Laila Shehata, Marti Tooley

Keywords(s): HSC Therapy, Hybridoma / Antibody, Immuno Oncology

Category(s): Therapeutic

Development of Fully Human Anti-Human Siglec-8 Antibodies as Basis for Therapeutics to Treat Eosinophilic and Mast Cell Disorders

Novel biologics targeting Siglec-8 to treat eosinophil-driven diseases Fully human mAbs, bispecific antibodies, and NK CARs that target Siglec-8. Siglec-8 is a transmembrane protein expressed on mature eosinophils, mast cells, and (to a lesser degree) basophils. Excessive eosinophil and mast cell activity have been implicated in the pathology...

Published: 2/12/2025 | Updated: 7/18/2023 | Inventor(s): Roland Walter, George Laszlo

Keywords(s): Hybridoma / Antibody, Immuno Oncology, Target

Category(s): Therapeutic

Chimeric and Humanized Anti-CD45 Antibody for Therapeutic Applications

Chimeric and Humanized Anti-CD45 Antibody for Therapeutic Applications Humanized antibody offers reduced toxicity and anti-mouse antibody immunization CD45 is a transmembrane cell surface glycoprotein expressed on almost all hematopoietic cells and absent on non-hematopoietic cells. CD45 is an abundantly expressed target in most hematologic...

Published: 12/6/2023 | Updated: 6/9/2022 | Inventor(s): Roland Walter, Brenda Sandmaier, David King, George Laszlo

Keywords(s): Hybridoma / Antibody, Immuno Oncology, Target

Category(s): Therapeutic

Notch ligand Delta 4 and anti-CD33 Bispecific Reagent for Treating Cancer and Other Diseases

Novel Bispecific to Alter the Immunosuppressive Tumor Microenvironment Compositions and methods of treatment of a novel bispecific reagent that targets Notch ligand to tumor sites. The tumor microenvironment (TME) consists of the complex ecosystem where cancerous cells reside and interact with their non-malignant neighbors, including immunosuppressive...

Published: 10/14/2024 | Updated: 10/4/2021 | Inventor(s): Irwin Bernstein, Vincent Luca, Kenan Garcia

Keywords(s): Hybridoma / Antibody, Immuno Oncology

Category(s): Therapeutic

Antibody, Therapeutic, and Companion Diagnostic approach targeting TRK B

Therapeutics and Diagnostics for Cancer Targeting a Novel TrkB Splice Variant Methods to treat or diagnose a variety of cancers using agents targeting a novel TrkB splice variant Cancer-driving mutations are found across a wide range of tumor types yet are often only present in a subset of tumor cells, making early detection and subsequent treatment...

Published: 5/4/2023 | Updated: 8/6/2020 | Inventor(s): Eric Holland, Siobhan Pattwell

Keywords(s): Hybridoma / Antibody

Category(s): Therapeutic

Immunostimulatory Capacity of Two Anti-Human NKG2D Monoclonal Antibodies

Monoclonal NKG2D Antibodies for the Treatment of Autoimmune and Inflammatory Disorders Two anti-human NKG2D monoclonal antibodies to specifically target and/or inhibit the NKG2D receptor on immune cells (e.g., CD4+ T cells). A precise balance of effector T cell activity is required to maintain effective immune surveillance without initiating...

Published: 4/6/2025 | Updated: 10/2/2019 | Inventor(s): Thomas Spies, Veronika Groh-Spies

Keywords(s): Hybridoma / Antibody

Category(s): Therapeutic

Novel Bispecific Antibody Targeting CD45

Pretargeted Radioimmunotherapy for the Treatment of of Acute Myeloid LeukemiaAn anti-CD45 bispecific antibody delivering targeted radioimmunotherapy to treat acute myeloid leukemia (AML), while avoiding systemic toxicity. Pretargeted radioimmunotherapy (PRIT) is a two-step approach that delivers radioactivity separate from the initial targeting step....

Published: 2/3/2025 | Updated: 10/25/2018 | Inventor(s): Johnnie Orozco

Keywords(s): Hybridoma / Antibody, Protein / Peptide

Category(s): Therapeutic

CD38 and BCMA Bispecific Antibody Pretargeted Radioimmunotherapy for Multiple Myeloma and other B Cell Malignancies

Pretargeted radioimmunotherapy for the treatment of Multiple Myeloma & B cell malignanciesAnti-CD38 and anti-BCMA bispecific antibodies deliver targeted radioimmunotherapy and avoid systemic toxicity. Pretargeted radioimmunotherapy (PRIT) differs from conventional RIT in that a nonradioactive bispecific targeting antibody is first administered allowing...

Published: 11/15/2023 | Updated: 8/20/2018 | Inventor(s): Damian Green, Yukang Lin, Oliver Press, Alice Tzeng, Karl Wittrup

Keywords(s): Hybridoma / Antibody, Immuno Oncology, Target

Category(s): Therapeutic

EBV antibodies

EBV Neutralizing Antibody and Vulnerability Site for Vaccine Design A human monoclonal antibody that neutralizes EBV infections in both B cells and epithelial cells, and new approaches to developing an EBV vaccine. Dr. McGuire and colleagues have isolated a human monoclonal antibody that binds the gH/gL protein on Epstein-Barr virus (EBV)....

Published: 2/4/2025 | Updated: 7/2/2018 | Inventor(s): Andrew Mcguire

Keywords(s): Hybridoma / Antibody

Category(s): Therapeutic, Vaccine